Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.

Aumann K, Frey AV, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M, Pahl HL.

Blood. 2013 Jul 4;122(1):93-9. doi: 10.1182/blood-2012-11-463257. Epub 2013 May 13.

2.

[Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].

Aumann K, Frey AV, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M, Pahl HL.

Pathologe. 2013 Nov;34 Suppl 2:201-9. doi: 10.1007/s00292-013-1824-8. German.

PMID:
24196613
3.

Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Yigit N, Covey S, Barouk-Fox S, Turker T, Geyer JT, Orazi A.

Hum Pathol. 2015 Aug;46(8):1217-25. doi: 10.1016/j.humpath.2015.05.004. Epub 2015 May 22.

PMID:
26093937
4.

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.

Barosi G.

Best Pract Res Clin Haematol. 2014 Jun;27(2):129-40. doi: 10.1016/j.beha.2014.07.004. Epub 2014 Jul 18. Review.

PMID:
25189724
5.

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.

Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.

PMID:
19616600
6.

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.

Barbui T, Thiele J, Vannucchi AM, Tefferi A.

Leukemia. 2013 Oct;27(10):1953-8. doi: 10.1038/leu.2013.74. Epub 2013 Mar 7. Review.

PMID:
23467025
7.

Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.

Muth M, Engelhardt BM, Kröger N, Hussein K, Schlué J, Büsche G, Kreipe HH, Bock O.

Ann Hematol. 2011 Jan;90(1):33-40. doi: 10.1007/s00277-010-1024-z. Epub 2010 Jul 13.

PMID:
20625903
8.

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.

Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H.

Haematologica. 2012 Mar;97(3):360-5. doi: 10.3324/haematol.2011.047811. Epub 2011 Nov 4.

9.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
10.

The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.

Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC.

APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17.

PMID:
21749449
11.

Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.

Rupoli S, Goteri G, Picardi P, Micucci G, Canafoglia L, Scortechini AR, Federici I, Giantomassi F, Da Lio L, Zizzi A, Honorati E, Leoni P.

Diagn Pathol. 2015 Apr 16;10:29. doi: 10.1186/s13000-015-0269-1.

12.

WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Kvasnicka HM.

Curr Hematol Malig Rep. 2013 Dec;8(4):333-41. doi: 10.1007/s11899-013-0186-x. Review.

PMID:
24146204
13.

Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.

Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC.

Histopathology. 2010 May;56(6):758-67. doi: 10.1111/j.1365-2559.2010.03545.x.

PMID:
20546341
14.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A.

J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11.

PMID:
21747083
16.

[The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].

Gong XB, Zhang XH, Lu XG, Tang QS, Gao X, Yang J.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jan;33(1):25-30. Chinese.

PMID:
22575188
17.
18.

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.

Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H.

Blood. 2011 May 26;117(21):5710-8. doi: 10.1182/blood-2010-07-293761. Epub 2011 Mar 29.

19.

MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis.

Ponce CC, Chauffaille Mde L, Ihara SS, Silva MR.

Leuk Res. 2012 Jan;36(1):93-7. doi: 10.1016/j.leukres.2011.06.024. Epub 2011 Jul 12.

PMID:
21752469
20.

Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis.

Geissler K, Jäger E, Gisslinger B, Thiele J, Schwarzinger I, Gisslinger H.

Am J Hematol. 2014 Dec;89(12):1157-8. doi: 10.1002/ajh.23829. Epub 2014 Aug 27. No abstract available.

Supplemental Content

Support Center